YD Bio Limited successfully completed its business combination with Breeze Holdings Acquisition Corp. and began trading on the Nasdaq Global Market on August 29, 2025, under ticker symbols "YDES" and "YDESW." The biotechnology company, which focuses on DNA methylation-based cancer detection technology and ophthalmologic innovations, raised over $11.5 million through the transaction to fund future operations.
The business combination was approved by Breeze shareholders at an extraordinary general meeting held on August 14, 2025. The proceeds from the PIPE offering, combined with cash released from the trust for former Breeze shareholders, positions YD Bio Ltd as an emerging leader in the biotech industry with growth potential across multiple healthcare markets.
DNA Methylation Cancer Detection Platform
YD Bio's core technology centers on proprietary DNA methylation-based detection methods for various cancers, developed through exclusive licensing agreements with partner EG BioMed. The company has made a screening test for early detection of pancreatic cancer available as a laboratory-developed test (LDT) through EG BioMed's CLIA-certified laboratory.
Additionally, YD Bio is preparing to launch a monitoring test for recurrent breast cancer as an LDT later this year. These blood-based cancer detection technologies represent the company's primary focus in oncology diagnostics, leveraging DNA methylation patterns to identify cancer presence and progression.
Ophthalmology Therapeutics Development
In partnership with 3D Global Biotech, YD Bio is advancing corneal stem cell and exosome technologies for treating ocular diseases including dry eye syndrome, glaucoma, and corneal injury. The company has obtained Institutional Review Board (IRB) approval for specimen collection and plans to initiate clinical trials evaluating exosome-based contact lenses and artificial tears in 2027.
These stem cell and exosome-based ophthalmology therapies represent a significant expansion of the company's therapeutic portfolio beyond cancer diagnostics into regenerative medicine applications.
Leadership and Business Evolution
Dr. Ethan Shen, Chairman and Chief Executive Officer with over 30 years of biomedical experience, leads YD Bio's transformation from its origins as a clinical trial drug supplier. Since founding in 2013, the company has evolved into a dynamic innovator in diagnostics and therapeutics while maintaining its role as a trusted supplier of investigational drugs and ancillary materials to global pharmaceutical companies.
"Since our founding in 2013, YD Bio has evolved from a supplier of clinical trial drugs and health supplements into a dynamic innovator in diagnostics and therapeutics," said Dr. Shen. "From pioneering exosome technologies to advancing early cancer detection, our progress reflects years of dedication and transformation."
Strategic Positioning and Market Advantages
YD Bio's business model centers on partnerships with biopharmaceutical companies to transform innovative technologies into commercially viable drugs and cancer detection diagnostics. The company's multi-decade exclusive licensing agreements, combined with proprietary patented technologies, provide a significant first-mover advantage across its clinical markets.
The company maintains a diversified portfolio spanning oncology diagnostics, regenerative medicine, and clinical trial support services. This broad approach positions YD Bio to capitalize on multiple fast-growing healthcare markets while leveraging its established relationships in the pharmaceutical industry.
The public listing enables YD Bio to accelerate innovation, scale production, and drive development and commercialization of its groundbreaking technologies across its three core program areas.
